Dr Fashoyin-Aje is a science-driven, board-certified internist and medical oncologist and Dr Fakhouri is a strategic leader with extensive experience in regulatory affairs
Parexel announced two Food and Drug Administration (FDA) luminaries have joined Parexel’s Consulting team – Lola Fashoyin-Aje, as Senior Vice President, Head of Regulatory Oncology, Cell & Gene and Tala Fakhouri, as Vice President Consulting, AI & Digital Policy, Real-World Research. .
Paul Bridges, President, Consulting, Parexel said, “These leadership appointments further demonstrate Parexel’s unrivalled regulatory expertise and our ability to help sponsors derisk their portfolios and navigate uncharted global regulatory processes, all while supporting patients in receiving these treatments sooner.”
Dr Fashoyin-Aje is a science-driven, board-certified internist and medical oncologist with a proven track record of accelerating drug approvals and developing and shaping innovative regulatory strategies. During her more than 30-year public health, medical and regulatory career, she has built extensive expertise in clinical development, regulatory policy and evidence standards, and collaboratively engaged stakeholders to drive innovation in drugs across varied product classes and diverse therapeutic areas.
Dr Fakhouri is a strategic leader with extensive experience in regulatory affairs, AI-driven drug development, real-world data analytics and digital health technology. She has demonstrated success in developing and interpreting complex regulatory landscapes, providing strategic regulatory guidance, and fostering collaborations between regulators, industry and global stakeholders.
